Cargando…
Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials
Azvudine (FNC) is a synthetic nucleoside analog used to treat adult patients living with human immunodeficiency virus-1 (HIV-1) infection with high viral load. After phosphorylation, Azvudine inhibits RNA-dependent RNA polymerase, leading to the discontinuation of RNA chain synthesis in viruses. In...
Autor principal: | Zhu, Ke-Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484631/ https://www.ncbi.nlm.nih.gov/pubmed/37693894 http://dx.doi.org/10.3389/fphar.2023.1228548 |
Ejemplares similares
-
Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients
por: de Souza, Sávio Bastos, et al.
Publicado: (2023) -
Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants
por: Zhang, Xi, et al.
Publicado: (2023) -
Efficacy and safety of azvudine in patients with COVID-19: A systematic review and meta-analysis
por: Chen, Zhaoyan, et al.
Publicado: (2023) -
Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching
por: Wei, An-Hua, et al.
Publicado: (2023) -
Azvudine (FNC): a promising clinical candidate for COVID-19 treatment
por: Yu, Bin, et al.
Publicado: (2020)